<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02538107</url>
  </required_header>
  <id_info>
    <org_study_id>ML21386</org_study_id>
    <nct_id>NCT02538107</nct_id>
  </id_info>
  <brief_title>An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant</brief_title>
  <official_title>Non-interventional, Observational Study to Investigate the Efficiency and Safety of Mircera in Patients With a Kidney Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This observational study will investigate efficacy and safety of methoxy
      polyethyleneglycol-epoetin beta in participants with a kidney transplant. Data of each
      participant will be collected over 15 months of Mircera therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2007</start_date>
  <completion_date type="Actual">November 30, 2011</completion_date>
  <primary_completion_date type="Actual">November 30, 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Hemoglobin Value of 11-12 Grams Per Deciliter (g/dL) From Visit 7 (Month 7) to Visit 9 (Month 9)</measure>
    <time_frame>From Month 7 to Month 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Hemoglobin Value of 11-13 g/dL From Visit 7 (Month 7) to Visit 9 (Month 9)</measure>
    <time_frame>From Month 7 to Month 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Hemoglobin Value of 11-13 g/dL From Visit 7 (Month 7) to Visit 12 (Month 12)</measure>
    <time_frame>From Month 7 to Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Hemoglobin Value of 11-13 g/dL From Visit 7 (Month 7) to Visit 15 (Month 15)</measure>
    <time_frame>From Month 7 to Month 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Hemoglobin Value of 10-13 g/dL From Visit 7 (Month 7) to Visit 12 (Month 12)</measure>
    <time_frame>From Month 7 to Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Hemoglobin Value of 10-13 g/dL From Visit 7 (Month 7) to Visit 15 (Month 15)</measure>
    <time_frame>From Month 7 to Month 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Duration in Months Mircera Was Administered at Current Dose After the Previous Dose Adjustment</measure>
    <time_frame>Up to 50 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Level Based on the Type of Kidney Transplantation Performed</measure>
    <time_frame>Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11, Month 12, Month 13, Month 14, Month 15 and Entire study (Month 1 to Month 15)</time_frame>
    <description>Participants were classified based on the type of kidney transplantation they underwent before entering in to the study in to two groups; participants who received living donation and participants who received cadaveric donation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Level Based on the Presence of Inflammatory Diseases</measure>
    <time_frame>Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11, Month 12, Month 13, Month 14, Month 15 and Entire study (Month 1 to Month 15)</time_frame>
    <description>Participants were classified based on the presence of other inflammatory diseases at baseline in to two groups; participants with presence of inflammatory diseases and participants with absence of inflammatory diseases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Level Based on the Etiology of Chronic Kidney Disease</measure>
    <time_frame>Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11, Month 12, Month 13, Month 14, Month 15 and Entire study (Month 1 to Month 15)</time_frame>
    <description>Participants were classified based on the etiology of chronic kidney disease. The different etiological reasons included diabetic vasculopathy, hypertensive nephrosclerosis, glomerulonephritis, polycystic kidney, chronic pyelonephritis, other reasons and origin unknown. Hemoglobin levels in participants who had etiology of chronic kidney disease as 'glomerulonephritis' or 'other reasons' were presented as these were the majority of the etiological reasons for chronic kidney disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Level Based on the Acute Bleeding Episode(s) During the Study</measure>
    <time_frame>Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11, Month 12, Month 13, Month 14, Month 15 and Entire study (Month 1 to Month 15)</time_frame>
    <description>Participants were classified in to two groups based on the presence of acute bleeding episodes during the study; presence or absence of bleeding episodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Level Based on the Glomerular Filtration Rate (GFR)</measure>
    <time_frame>Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11, Month 12, Month 13, Month 14, Month 15 and Entire study (Month 1 to Month 15)</time_frame>
    <description>GFR is described as the flow rate of filtered fluid through the kidney and was determined using the Cockcroft-Gault formula to calculate the creatinine clearance. For males, creatinine clearance [milliliters per minute (mL/min)] = [(140 minus age) multiplied by (*) (body weight in kilogram [kg]) divided by [72 * serum creatinine milligrams per deciliter (mg/dL)]. For females, creatinine clearance (mL/min) = 0.85 * [(140 minus age) * (body weight in kg)] divided by [72 * serum creatinine (mg/dL)]. Participants were classified based on the GFR in to two groups; GFR less than (&lt;) 30 mL/min and in the range of 30-60 mL/min and hemoglobin levels at different visits were presented.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">290</enrollment>
  <condition>Anemia, Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Kidney Transplant Participants</arm_group_label>
    <description>Participants with kidney transplant and a chronic kidney disease who were receiving methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methoxy-polyethyleneglycol epoetin beta</intervention_name>
    <arm_group_label>Kidney Transplant Participants</arm_group_label>
    <other_name>Mircera</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with kidney transplant prescribed methoxy polyethyleneglycol-epoetin beta
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with kidney transplant and a chronic kidney disease (CKD), who need
             erythropoiesis stimulating agent (ESA) therapy as part of their medical care and
             prescribed methoxy polyethyleneglycol-epoetin beta by the doctor.

          -  The transplant should function regularly and without need of continuous dialysis
             treatment at inclusion and also during the documentation period of this study
             according to treating physician's prognosis.

        Exclusion Criteria:

          -  Kidney transplantation dates back less than 3 months. Acute decrease of hemoglobin
             (Hb) before enrollment, defined as decrease of greater than or equal to (&gt;/=) 2 g/dL
             between two sequential values.

          -  Administration of other ESA therapies during the observation period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Hann. Münden, Nephrologisches Zentrum Niedersachsen</name>
      <address>
        <city>Hann. Münden</city>
        <zip>34346</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <results_first_submitted>October 5, 2015</results_first_submitted>
  <results_first_submitted_qc>October 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 3, 2015</results_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Kidney Transplant Participants</title>
          <description>Participants with chronic kidney disease who underwent kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="290"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive any Mircera dose</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Necessity of dialysis</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administration of other ESA</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No further treatment necessary</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not recorded</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set included participants who received at least 1 dose of study treatment. Age was reported for N=278 participants since data for 1 participant was missing.</population>
      <group_list>
        <group group_id="B1">
          <title>Kidney Transplant Participants</title>
          <description>Participants with chronic kidney disease who underwent kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="279"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.1" spread="14.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Hemoglobin Value of 11-12 Grams Per Deciliter (g/dL) From Visit 7 (Month 7) to Visit 9 (Month 9)</title>
        <time_frame>From Month 7 to Month 9</time_frame>
        <population>Efficacy analysis set (Included participants who reported no pregnancy during the study period and had dosing and hemoglobin data available during 1 of the 3 visits [Visits 7-9]).</population>
        <group_list>
          <group group_id="O1">
            <title>Kidney Transplant Participants</title>
            <description>Participants with chronic kidney disease who underwent kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Hemoglobin Value of 11-12 Grams Per Deciliter (g/dL) From Visit 7 (Month 7) to Visit 9 (Month 9)</title>
          <population>Efficacy analysis set (Included participants who reported no pregnancy during the study period and had dosing and hemoglobin data available during 1 of the 3 visits [Visits 7-9]).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Hemoglobin Value of 11-13 g/dL From Visit 7 (Month 7) to Visit 9 (Month 9)</title>
        <time_frame>From Month 7 to Month 9</time_frame>
        <population>Efficacy analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Kidney Transplant Participants</title>
            <description>Participants with chronic kidney disease who underwent kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Hemoglobin Value of 11-13 g/dL From Visit 7 (Month 7) to Visit 9 (Month 9)</title>
          <population>Efficacy analysis set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Hemoglobin Value of 11-13 g/dL From Visit 7 (Month 7) to Visit 12 (Month 12)</title>
        <time_frame>From Month 7 to Month 12</time_frame>
        <population>Efficacy analysis set. Participants who were evaluable at the specified time frame were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Kidney Transplant Participants</title>
            <description>Participants with chronic kidney disease who underwent kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Hemoglobin Value of 11-13 g/dL From Visit 7 (Month 7) to Visit 12 (Month 12)</title>
          <population>Efficacy analysis set. Participants who were evaluable at the specified time frame were included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Hemoglobin Value of 11-13 g/dL From Visit 7 (Month 7) to Visit 15 (Month 15)</title>
        <time_frame>From Month 7 to Month 15</time_frame>
        <population>Efficacy analysis set. Participants who were evaluable at the specified time frame were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Kidney Transplant Participants</title>
            <description>Participants with chronic kidney disease who underwent kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Hemoglobin Value of 11-13 g/dL From Visit 7 (Month 7) to Visit 15 (Month 15)</title>
          <population>Efficacy analysis set. Participants who were evaluable at the specified time frame were included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Hemoglobin Value of 10-13 g/dL From Visit 7 (Month 7) to Visit 12 (Month 12)</title>
        <time_frame>From Month 7 to Month 12</time_frame>
        <population>Efficacy analysis set. Participants who were evaluable at the specified time frame were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Kidney Transplant Participants</title>
            <description>Participants with chronic kidney disease who underwent kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Hemoglobin Value of 10-13 g/dL From Visit 7 (Month 7) to Visit 12 (Month 12)</title>
          <population>Efficacy analysis set. Participants who were evaluable at the specified time frame were included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Level Based on the Type of Kidney Transplantation Performed</title>
        <description>Participants were classified based on the type of kidney transplantation they underwent before entering in to the study in to two groups; participants who received living donation and participants who received cadaveric donation.</description>
        <time_frame>Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11, Month 12, Month 13, Month 14, Month 15 and Entire study (Month 1 to Month 15)</time_frame>
        <population>Efficacy analysis set. n = number of participants who were evaluable at a particular visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Living Donation-Kidney Transplant Participants</title>
            <description>Participants with chronic kidney disease who underwent 'living donation' type of kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
          </group>
          <group group_id="O2">
            <title>Cadaveric Donation-Kidney Transplant Participants</title>
            <description>Participants with chronic kidney disease who underwent 'cadaveric donation' type of kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Level Based on the Type of Kidney Transplantation Performed</title>
          <description>Participants were classified based on the type of kidney transplantation they underwent before entering in to the study in to two groups; participants who received living donation and participants who received cadaveric donation.</description>
          <population>Efficacy analysis set. n = number of participants who were evaluable at a particular visit.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Month 1) (n=22, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.08" spread="1.244"/>
                    <measurement group_id="O2" value="11.26" spread="1.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Month 2) (n=25, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.37" spread="1.215"/>
                    <measurement group_id="O2" value="11.41" spread="1.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Month 3) (n=27, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.34" spread="1.163"/>
                    <measurement group_id="O2" value="11.71" spread="1.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Month 4) (n=23, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.30" spread="1.213"/>
                    <measurement group_id="O2" value="11.56" spread="1.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Month 5) (n=25, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.74" spread="1.174"/>
                    <measurement group_id="O2" value="11.75" spread="1.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Month 6) (n=20, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.08" spread="0.896"/>
                    <measurement group_id="O2" value="11.66" spread="1.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7 (Month 7) (n=21, 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.23" spread="1.132"/>
                    <measurement group_id="O2" value="11.59" spread="1.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8 (Month 8) (n=24, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.18" spread="1.305"/>
                    <measurement group_id="O2" value="11.57" spread="1.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Month 9) (n=17, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.36" spread="1.386"/>
                    <measurement group_id="O2" value="11.60" spread="1.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 10 (Month 10) (n=21, 107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.26" spread="1.435"/>
                    <measurement group_id="O2" value="11.59" spread="1.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Month 11) (n=18, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.46" spread="1.079"/>
                    <measurement group_id="O2" value="11.62" spread="1.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12 (Month 12) (n=22, 110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.12" spread="1.437"/>
                    <measurement group_id="O2" value="11.41" spread="1.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 13 (Month 13) (n=23, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.86" spread="1.386"/>
                    <measurement group_id="O2" value="11.32" spread="1.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Month 14) (n=18, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.21" spread="1.018"/>
                    <measurement group_id="O2" value="11.35" spread="1.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 15 (Month 15) (n=21, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.05" spread="1.187"/>
                    <measurement group_id="O2" value="11.50" spread="1.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Entire study (Month 1 to Month 15) (n=34, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.25" spread="0.853"/>
                    <measurement group_id="O2" value="11.49" spread="0.830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Level Based on the Presence of Inflammatory Diseases</title>
        <description>Participants were classified based on the presence of other inflammatory diseases at baseline in to two groups; participants with presence of inflammatory diseases and participants with absence of inflammatory diseases.</description>
        <time_frame>Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11, Month 12, Month 13, Month 14, Month 15 and Entire study (Month 1 to Month 15)</time_frame>
        <population>Efficacy analysis set. n = number of participants who were evaluable at a particular visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Inflammatory Diseases Present-Kidney Transplant Participants</title>
            <description>Participants with chronic kidney disease and presence of other inflammatory diseases at baseline who underwent kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
          </group>
          <group group_id="O2">
            <title>Inflammatory Diseases Absent-Kidney Transplant Participants</title>
            <description>Participants with chronic kidney disease and absence of other inflammatory diseases at baseline who underwent kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Level Based on the Presence of Inflammatory Diseases</title>
          <description>Participants were classified based on the presence of other inflammatory diseases at baseline in to two groups; participants with presence of inflammatory diseases and participants with absence of inflammatory diseases.</description>
          <population>Efficacy analysis set. n = number of participants who were evaluable at a particular visit.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Month 1) (n=41, 94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.30" spread="1.168"/>
                    <measurement group_id="O2" value="11.20" spread="1.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Month 2) (n=43, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.33" spread="1.231"/>
                    <measurement group_id="O2" value="11.44" spread="1.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Month 3) (n=45, 110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.75" spread="1.419"/>
                    <measurement group_id="O2" value="11.61" spread="1.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Month 4) (n=47, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.54" spread="1.209"/>
                    <measurement group_id="O2" value="11.51" spread="1.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Month 5) (n=43, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.71" spread="1.135"/>
                    <measurement group_id="O2" value="11.76" spread="1.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Month 6) (n=42, 91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.34" spread="1.068"/>
                    <measurement group_id="O2" value="11.68" spread="1.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7 (Month 7) (n=40, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.46" spread="1.276"/>
                    <measurement group_id="O2" value="11.56" spread="1.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8 (Month 8) (n=40, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.58" spread="1.324"/>
                    <measurement group_id="O2" value="11.46" spread="1.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Month 9) (n=42, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.61" spread="1.236"/>
                    <measurement group_id="O2" value="11.55" spread="1.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 10 (Month 10) (n=34, 94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.63" spread="0.996"/>
                    <measurement group_id="O2" value="11.50" spread="1.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Month 11) (n=34, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.75" spread="1.015"/>
                    <measurement group_id="O2" value="11.53" spread="1.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12 (Month 12) (n=33, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.23" spread="1.095"/>
                    <measurement group_id="O2" value="11.41" spread="1.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 13 (Month 13) (n=36, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.17" spread="1.129"/>
                    <measurement group_id="O2" value="11.26" spread="1.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Month 14) (n=31, 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.07" spread="1.090"/>
                    <measurement group_id="O2" value="11.42" spread="1.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 15 (Month 15) (n=27, 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.03" spread="1.157"/>
                    <measurement group_id="O2" value="11.55" spread="1.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Entire study (Month 1 to Month 15) (n=56, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.38" spread="0.730"/>
                    <measurement group_id="O2" value="11.48" spread="0.878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Level Based on the Etiology of Chronic Kidney Disease</title>
        <description>Participants were classified based on the etiology of chronic kidney disease. The different etiological reasons included diabetic vasculopathy, hypertensive nephrosclerosis, glomerulonephritis, polycystic kidney, chronic pyelonephritis, other reasons and origin unknown. Hemoglobin levels in participants who had etiology of chronic kidney disease as 'glomerulonephritis' or 'other reasons' were presented as these were the majority of the etiological reasons for chronic kidney disease.</description>
        <time_frame>Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11, Month 12, Month 13, Month 14, Month 15 and Entire study (Month 1 to Month 15)</time_frame>
        <population>Efficacy analysis set. Participants who were evaluable for the specified group were included and n = number of participants who were evaluable at a particular visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Glomerulonephritis-Kidney Transplant Participants</title>
            <description>Participants with glomerulonephritis as the cause of chronic kidney disease who underwent kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
          </group>
          <group group_id="O2">
            <title>Other Reason-Kidney Transplant Participants</title>
            <description>Participants with unspecified other reasons as the cause of chronic kidney disease who underwent kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Level Based on the Etiology of Chronic Kidney Disease</title>
          <description>Participants were classified based on the etiology of chronic kidney disease. The different etiological reasons included diabetic vasculopathy, hypertensive nephrosclerosis, glomerulonephritis, polycystic kidney, chronic pyelonephritis, other reasons and origin unknown. Hemoglobin levels in participants who had etiology of chronic kidney disease as 'glomerulonephritis' or 'other reasons' were presented as these were the majority of the etiological reasons for chronic kidney disease.</description>
          <population>Efficacy analysis set. Participants who were evaluable for the specified group were included and n = number of participants who were evaluable at a particular visit.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Month 1) (n=43, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.27" spread="1.254"/>
                    <measurement group_id="O2" value="11.44" spread="1.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Month 2) (n=43, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.42" spread="1.240"/>
                    <measurement group_id="O2" value="11.48" spread="1.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Month 3) (n=49, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.79" spread="1.298"/>
                    <measurement group_id="O2" value="11.75" spread="1.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Month 4) (n=49, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.37" spread="1.270"/>
                    <measurement group_id="O2" value="11.76" spread="1.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Month 5) (n=46, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.88" spread="1.156"/>
                    <measurement group_id="O2" value="11.72" spread="1.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Month 6) (n=40, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.62" spread="1.129"/>
                    <measurement group_id="O2" value="11.68" spread="1.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7 (Month 7) (n=46, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.71" spread="1.270"/>
                    <measurement group_id="O2" value="11.52" spread="1.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8 (Month 8) (n=39, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.71" spread="1.305"/>
                    <measurement group_id="O2" value="11.60" spread="1.439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Month 9) (n=45, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.88" spread="1.126"/>
                    <measurement group_id="O2" value="11.46" spread="1.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 10 (Month 10) (n=44, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.60" spread="1.266"/>
                    <measurement group_id="O2" value="11.67" spread="1.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Month 11) (n=33, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.96" spread="1.236"/>
                    <measurement group_id="O2" value="11.47" spread="1.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12 (Month 12) (n=36, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.33" spread="1.452"/>
                    <measurement group_id="O2" value="11.37" spread="1.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 13 (Month 13) (n=41, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.32" spread="1.530"/>
                    <measurement group_id="O2" value="11.20" spread="1.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Month 14) (n=40, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.59" spread="1.077"/>
                    <measurement group_id="O2" value="11.26" spread="1.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 15 (Month 15) (n=35, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.40" spread="1.296"/>
                    <measurement group_id="O2" value="11.47" spread="1.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Entire study (Month 1 to Month 15) (n=60, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.52" spread="0.924"/>
                    <measurement group_id="O2" value="11.52" spread="0.876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Level Based on the Acute Bleeding Episode(s) During the Study</title>
        <description>Participants were classified in to two groups based on the presence of acute bleeding episodes during the study; presence or absence of bleeding episodes.</description>
        <time_frame>Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11, Month 12, Month 13, Month 14, Month 15 and Entire study (Month 1 to Month 15)</time_frame>
        <population>Efficacy analysis set. Participants who were evaluable for the specified group were included and n = number of participants who were evaluable at a particular visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Absence of Acute Bleeding-Kidney Transplant Participants</title>
            <description>Participants with absence of acute bleeding episodes during the study with chronic kidney disease who underwent kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
          </group>
          <group group_id="O2">
            <title>Presence of Acute Bleeding-Kidney Transplant Participants</title>
            <description>Participants with presence of acute bleeding episodes during the study with chronic kidney disease who underwent kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Level Based on the Acute Bleeding Episode(s) During the Study</title>
          <description>Participants were classified in to two groups based on the presence of acute bleeding episodes during the study; presence or absence of bleeding episodes.</description>
          <population>Efficacy analysis set. Participants who were evaluable for the specified group were included and n = number of participants who were evaluable at a particular visit.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Month 1) (n=135, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.23" spread="1.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Month 2) (n=142, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.40" spread="1.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Month 3) (n=155, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.65" spread="1.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Month 4) (n=150, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.51" spread="1.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Month 5) (n=147, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.75" spread="1.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Month 6) (n=132, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.57" spread="1.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7 (Month 7) (n=141, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.53" spread="1.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8 (Month 8) (n=137, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.50" spread="1.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Month 9) (n=141, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.57" spread="1.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 10 (Month 10) (n=128, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.53" spread="1.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Month 11) (n=116, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.59" spread="1.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12 (Month 12) (n=132, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.37" spread="1.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 13 (Month 13) (n=122, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.24" spread="1.285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Month 14) (n=118, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.32" spread="1.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 15 (Month 15) (n=104, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.40" spread="1.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Entire study (Month 1 to Month 15) (n=192, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.45" spread="0.839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Level Based on the Glomerular Filtration Rate (GFR)</title>
        <description>GFR is described as the flow rate of filtered fluid through the kidney and was determined using the Cockcroft-Gault formula to calculate the creatinine clearance. For males, creatinine clearance [milliliters per minute (mL/min)] = [(140 minus age) multiplied by (*) (body weight in kilogram [kg]) divided by [72 * serum creatinine milligrams per deciliter (mg/dL)]. For females, creatinine clearance (mL/min) = 0.85 * [(140 minus age) * (body weight in kg)] divided by [72 * serum creatinine (mg/dL)]. Participants were classified based on the GFR in to two groups; GFR less than (&lt;) 30 mL/min and in the range of 30-60 mL/min and hemoglobin levels at different visits were presented.</description>
        <time_frame>Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 7, Month 8, Month 9, Month 10, Month 11, Month 12, Month 13, Month 14, Month 15 and Entire study (Month 1 to Month 15)</time_frame>
        <population>Efficacy analysis set. Participants who were evaluable for the specified group were included and n = number of participants who were evaluable at a particular visit.</population>
        <group_list>
          <group group_id="O1">
            <title>GFR (&lt;30 mL/Min)-Kidney Transplant Participants</title>
            <description>Participants with GFR &lt;30 mL/min with chronic kidney disease who underwent kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
          </group>
          <group group_id="O2">
            <title>GFR (30-60 mL/Min)-Kidney Transplant Participants</title>
            <description>Participants with GFR in the range of 30-60 mL/min with chronic kidney disease who underwent kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Level Based on the Glomerular Filtration Rate (GFR)</title>
          <description>GFR is described as the flow rate of filtered fluid through the kidney and was determined using the Cockcroft-Gault formula to calculate the creatinine clearance. For males, creatinine clearance [milliliters per minute (mL/min)] = [(140 minus age) multiplied by (*) (body weight in kilogram [kg]) divided by [72 * serum creatinine milligrams per deciliter (mg/dL)]. For females, creatinine clearance (mL/min) = 0.85 * [(140 minus age) * (body weight in kg)] divided by [72 * serum creatinine (mg/dL)]. Participants were classified based on the GFR in to two groups; GFR less than (&lt;) 30 mL/min and in the range of 30-60 mL/min and hemoglobin levels at different visits were presented.</description>
          <population>Efficacy analysis set. Participants who were evaluable for the specified group were included and n = number of participants who were evaluable at a particular visit.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Month 1) (n=35, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.15" spread="0.952"/>
                    <measurement group_id="O2" value="11.44" spread="1.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Month 2) (n=35, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.17" spread="1.234"/>
                    <measurement group_id="O2" value="11.42" spread="1.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Month 3) (n=40, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.60" spread="1.205"/>
                    <measurement group_id="O2" value="11.65" spread="0.954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Month 4) (n=37, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.26" spread="1.242"/>
                    <measurement group_id="O2" value="11.75" spread="1.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Month 5) (n=37, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.40" spread="1.090"/>
                    <measurement group_id="O2" value="11.87" spread="1.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Month 6) (n=34, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.32" spread="1.158"/>
                    <measurement group_id="O2" value="11.90" spread="1.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7 (Month 7) (n=36, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.46" spread="1.108"/>
                    <measurement group_id="O2" value="11.62" spread="1.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8 (Month 8) (n=28, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.46" spread="1.215"/>
                    <measurement group_id="O2" value="11.66" spread="1.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Month 9) (n=38, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.50" spread="1.369"/>
                    <measurement group_id="O2" value="11.85" spread="1.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 10 (Month 10) (n=30, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.22" spread="1.063"/>
                    <measurement group_id="O2" value="11.88" spread="0.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Month 11) (n=30, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.55" spread="1.071"/>
                    <measurement group_id="O2" value="11.69" spread="1.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12 (Month 12) (n=27, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.41" spread="0.943"/>
                    <measurement group_id="O2" value="11.67" spread="1.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 13 (Month 13) (n=31, 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.44" spread="1.048"/>
                    <measurement group_id="O2" value="11.41" spread="1.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 14 (Month 14) (n=27, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.29" spread="1.056"/>
                    <measurement group_id="O2" value="11.40" spread="1.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 15 (Month 15) (n=24, 35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.20" spread="1.093"/>
                    <measurement group_id="O2" value="11.81" spread="0.993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Entire study (Month 1 to Month 15) (n=46, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.26" spread="0.784"/>
                    <measurement group_id="O2" value="11.62" spread="0.716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Hemoglobin Value of 10-13 g/dL From Visit 7 (Month 7) to Visit 15 (Month 15)</title>
        <time_frame>From Month 7 to Month 15</time_frame>
        <population>Efficacy analysis set. Participants who were evaluable at the specified time frame were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Kidney Transplant Participants</title>
            <description>Participants with chronic kidney disease who underwent kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Hemoglobin Value of 10-13 g/dL From Visit 7 (Month 7) to Visit 15 (Month 15)</title>
          <population>Efficacy analysis set. Participants who were evaluable at the specified time frame were included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Duration in Months Mircera Was Administered at Current Dose After the Previous Dose Adjustment</title>
        <time_frame>Up to 50 months</time_frame>
        <population>Efficacy analysis set. Participants with non-missing values were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Kidney Transplant Participants</title>
            <description>Participants with chronic kidney disease who underwent kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Duration in Months Mircera Was Administered at Current Dose After the Previous Dose Adjustment</title>
          <population>Efficacy analysis set. Participants with non-missing values were included.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.31" spread="6.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 50 months</time_frame>
      <desc>Safety analysis set.</desc>
      <group_list>
        <group group_id="E1">
          <title>Kidney Transplant Participants</title>
          <description>Participants with chronic kidney disease who underwent kidney transplantation and received methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care were observed and documented for up to 15 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Human polyomavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>VIth nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Dialysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Haemodialysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Parathyroidectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Macrocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Tympanic membrane disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Shunt occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Phantom pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Hirsutism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Night Sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Walking disability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel decompression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-LaRoche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

